Premium
Subacute cutaneous lupus erythematosus with positive anti‐Ro antibodies following palbociclib and letrozole treatment: A case report and literature review
Author(s) -
RussellGoldman Eleanor,
Nazarian Rosalynn M.
Publication year - 2020
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.13673
Subject(s) - medicine , palbociclib , subacute cutaneous lupus erythematosus , letrozole , dermatology , breast cancer , cancer , pathology , antibody , metastatic breast cancer , immunology , connective tissue disease , aromatase , autoimmune disease
Drug‐induced subacute cutaneous lupus erythematosus (DI‐SCLE) is an uncommon but well‐described phenomenon, most often seen in association with antihypertensives and antifungal medications. In recent years, rare reports of DI‐SCLE have been described in patients being treated with targeted therapies. Herein, we describe a case of DI‐SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer. This report is the first known case of DI‐SCLE with positive anti‐Ro antibodies in this setting. We also summarize the literature describing DI‐SCLE in association with targeted therapies to date and its possible association with dysregulation of the vascular endothelial growth factor pathway.